Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Safflor yellow is a water-soluble mixture of chalcone glycosides extracted from the dried flowers of Carthamus tinctorius L. (safflower). It is a traditional Chinese medicine ingredient known for its ability to "activate blood circulation and remove blood stasis," and is widely used in China for cardiovascular and cerebrovascular diseases. The primary active constituent is Hydroxysafflor Yellow A (HSYA), which exhibits antioxidant, anti-inflammatory, anticoagulant, antiplatelet aggregation, vasodilatory, neuroprotective, and cardioprotective effects. Mechanistically, safflor yellow components modulate multiple pathways including inhibition of platelet aggregation via arachidonic acid metabolism blockade; reduction of inflammation; protection against ischemia-reperfusion injury; improvement of microcirculation; and promotion of apoptosis in damaged cells through TGF-beta/Smad signaling modulation[2][3][6][7]. Clinical use focuses on improving outcomes in myocardial ischemia/reperfusion injury and cerebral ischemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on safflor yellow.